Mechlorethamine, procarbazine and prednisone for the treatment of resistant lymphoma in dogs.
Vet Comp Oncol
; 7(1): 38-44, 2009 Mar.
Article
em En
| MEDLINE
| ID: mdl-19222829
ABSTRACT
Forty-one dogs with resistant lymphoma were treated with a modified MOPP (mechlorethamine, vincristine, procarbazine and prednisone) protocol (MPP [mechlorethamine, procarbazine and prednisone] administered on a 21-day cycle, shortened from the 28-day MOPP cycle). The overall response rate to MPP was 34% for a median of 56 days (95% confidence interval 30-238). Seventeen percent of dogs had a complete response for a median duration of 238 days, 17% had a partial response for a median of 56 days and 32% had stable disease for a median of 24 days. Histological grade or cell morphology on cytology was associated with response. Minimal toxicity was observed with the MPP protocol, suggesting that further dose intensification or addition of another chemotherapeutic agent would be possible.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Resistencia a Medicamentos Antineoplásicos
/
Doenças do Cão
/
Linfoma
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article